Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now dis...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ELLEN MYRA DOBRUSIN INDERJIT S. SIDHU PETER LAURENCE TOOGOOD YADAGIRI BATHINI RONALD GEORGE MICETICH MARK ROBERT BARVIAN RAJESHWAR SINGH ROY THOMAS WINTERS JAMES STANLEY KALTENBRONN |
| description | This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provides useful intermediates generated during the production of the quinazoline compounds. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU1462101A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU1462101A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU1462101A3</originalsourceid><addsrcrecordid>eNrjZPAMLM3MS6zKz8nMSy1WSMxLUSjJSM0sUigtTlVIyy9SyMzLyEzKLMnMS1dIrkwGqtJNSS1IzUtJzStRyAbqBCpLzauqzE0t5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8Y6hhiZmRoYGho7GhFUAAEtANEo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes</title><source>esp@cenet</source><creator>ELLEN MYRA DOBRUSIN ; INDERJIT S. SIDHU ; PETER LAURENCE TOOGOOD ; YADAGIRI BATHINI ; RONALD GEORGE MICETICH ; MARK ROBERT BARVIAN ; RAJESHWAR SINGH ; ROY THOMAS WINTERS ; JAMES STANLEY KALTENBRONN</creator><creatorcontrib>ELLEN MYRA DOBRUSIN ; INDERJIT S. SIDHU ; PETER LAURENCE TOOGOOD ; YADAGIRI BATHINI ; RONALD GEORGE MICETICH ; MARK ROBERT BARVIAN ; RAJESHWAR SINGH ; ROY THOMAS WINTERS ; JAMES STANLEY KALTENBRONN</creatorcontrib><description>This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provides useful intermediates generated during the production of the quinazoline compounds.</description><edition>7</edition><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2001</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010604&DB=EPODOC&CC=AU&NR=1462101A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010604&DB=EPODOC&CC=AU&NR=1462101A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ELLEN MYRA DOBRUSIN</creatorcontrib><creatorcontrib>INDERJIT S. SIDHU</creatorcontrib><creatorcontrib>PETER LAURENCE TOOGOOD</creatorcontrib><creatorcontrib>YADAGIRI BATHINI</creatorcontrib><creatorcontrib>RONALD GEORGE MICETICH</creatorcontrib><creatorcontrib>MARK ROBERT BARVIAN</creatorcontrib><creatorcontrib>RAJESHWAR SINGH</creatorcontrib><creatorcontrib>ROY THOMAS WINTERS</creatorcontrib><creatorcontrib>JAMES STANLEY KALTENBRONN</creatorcontrib><title>Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes</title><description>This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provides useful intermediates generated during the production of the quinazoline compounds.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2001</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPAMLM3MS6zKz8nMSy1WSMxLUSjJSM0sUigtTlVIyy9SyMzLyEzKLMnMS1dIrkwGqtJNSS1IzUtJzStRyAbqBCpLzauqzE0t5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8Y6hhiZmRoYGho7GhFUAAEtANEo</recordid><startdate>20010604</startdate><enddate>20010604</enddate><creator>ELLEN MYRA DOBRUSIN</creator><creator>INDERJIT S. SIDHU</creator><creator>PETER LAURENCE TOOGOOD</creator><creator>YADAGIRI BATHINI</creator><creator>RONALD GEORGE MICETICH</creator><creator>MARK ROBERT BARVIAN</creator><creator>RAJESHWAR SINGH</creator><creator>ROY THOMAS WINTERS</creator><creator>JAMES STANLEY KALTENBRONN</creator><scope>EVB</scope></search><sort><creationdate>20010604</creationdate><title>Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes</title><author>ELLEN MYRA DOBRUSIN ; INDERJIT S. SIDHU ; PETER LAURENCE TOOGOOD ; YADAGIRI BATHINI ; RONALD GEORGE MICETICH ; MARK ROBERT BARVIAN ; RAJESHWAR SINGH ; ROY THOMAS WINTERS ; JAMES STANLEY KALTENBRONN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU1462101A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2001</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ELLEN MYRA DOBRUSIN</creatorcontrib><creatorcontrib>INDERJIT S. SIDHU</creatorcontrib><creatorcontrib>PETER LAURENCE TOOGOOD</creatorcontrib><creatorcontrib>YADAGIRI BATHINI</creatorcontrib><creatorcontrib>RONALD GEORGE MICETICH</creatorcontrib><creatorcontrib>MARK ROBERT BARVIAN</creatorcontrib><creatorcontrib>RAJESHWAR SINGH</creatorcontrib><creatorcontrib>ROY THOMAS WINTERS</creatorcontrib><creatorcontrib>JAMES STANLEY KALTENBRONN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ELLEN MYRA DOBRUSIN</au><au>INDERJIT S. SIDHU</au><au>PETER LAURENCE TOOGOOD</au><au>YADAGIRI BATHINI</au><au>RONALD GEORGE MICETICH</au><au>MARK ROBERT BARVIAN</au><au>RAJESHWAR SINGH</au><au>ROY THOMAS WINTERS</au><au>JAMES STANLEY KALTENBRONN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes</title><date>2001-06-04</date><risdate>2001</risdate><abstract>This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-quinazolines (I) and (II) that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provides useful intermediates generated during the production of the quinazoline compounds.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU1462101A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T00%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ELLEN%20MYRA%20DOBRUSIN&rft.date=2001-06-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU1462101A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |